We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Lecanemab: A Hopeful Alzheimer's Disease Treatment.
- Authors
Mughal, Zaib Un Nisa; Ahmed, Bisma; Amin, Fatima; Sadiq, Aiman; Rangwala, Burhanuddin Sohail
- Abstract
Lecanemab, also known as Leqembi, is a monoclonal antibody medication that has been approved by the FDA for the treatment of Alzheimer's disease (AD). It targets and reduces the accumulation of amyloid-beta (Aβ) plaques in the brain, which are characteristic of AD. Clinical trials have shown that Lecanemab effectively reduces brain amyloid plaques compared to a placebo, but it is also associated with some negative side effects. Further research is needed to determine its overall effectiveness as a therapy for AD.
- Subjects
ALZHEIMER'S disease; THERAPEUTICS; LECANEMAB; CEREBROSPINAL fluid examination; CEREBRAL amyloid angiopathy
- Publication
Annals of Neurosciences, 2024, Vol 31, Issue 2, p83
- ISSN
0972-7531
- Publication type
Article
- DOI
10.1177/09727531231189925